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Objectives: There is no consensus for the best postoperative follow-up in
patients after complete resection of non–small cell lung cancer. Low-dose
computed tomography of chest proves valuable in screening primary lung
cancer and may be a useful tool in postoperative surveillance.
Methods: In part 1, 30 patients who underwent surgical resection of
non–small cell lung cancer and were at the first (n  14), second (n  9),
or fifth (n  7) annual postoperative surveillance were selected chrono-
logically and subjected to chest radiography, low-dose computed tomog-
raphy, and standard-dose computed tomography to verify the diagnostic
accuracy of low-dose computed tomography. In part 2, 43 patients were prospec-
tively enrolled and followed up regularly after complete resection of non-small cell
lung cancer. The follow-up protocol included physical examination, sputum cytol-
ogy, serum carcinoembryonic antigen, chest radiography, and low-dose computed
tomography every 3 months in the first 2 years postoperatively until tumor recurrence.
Results: In part 1, tumor recurrence was detected by standard-dose computed
tomography in 7 cases. Low-dose computed tomography and chest radiography
missed 1 and 5 of 7 cases, respectively. In part 2, tumor recurrence was found in 14
cases with 19 metastatic sites. Thirteen of the 14 (92.9%) cases were detected by
scheduled visiting and 11 (78.6%) detected by low-dose computed tomography
including the 7 without symptoms. Of the 19 recurrent sites found in 14 patients, 11
ones (57.9%) were detected by low-dose computed tomography.
Conclusions: Low-dose computed tomography may be of considerable value in
early detection of tumor recurrence in postoperative non–small cell lung cancer
patients. Further large prospective studies are needed to verify this issue.
Lung cancer is the leading cause of cancer-related death in manycountries, including Taiwan.1 Despite recent progress in surgical andmedical treatment, the 5-year survival rate of lung cancer patientshas improved little. About 80% of lung cancers are non–small celllung cancer (NSCLC), but only 20% of the patients can undergocurative surgical resection. Furthermore, almost half of the initially
regarded as “completely” removed NSCLC will recur within 5 years.2,3 Regular
postoperative follow-up is mandatory because of high rate of tumor recurrence and
increased lifetime risk of developing second primary lung cancer in these patients.
Nevertheless, the follow-up strategies appear to be divergent and no consensus has
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ever been made.4 Several studies attempted to verify this
issue but failed to show the survival benefit of regular
postoperative follow-up.3,5-7 The reasons remain unknown.
However, the limitation of retrospective studies report-
ed3,5-7 and the inadequate intensity and/or detection meth-
ods used in follow-up strategies may explain it in part.
Accordingly, prospective studies designed to evaluate the
benefit of intensive follow-up protocol, including new de-
tecting methods for postoperative NSCLC patients, are war-
ranted. To our knowledge, there was only one prospective
study designed to evaluate the feasibility of an intensive
follow-up protocol.8
Because of the inherent good contrast and low radiation
absorption of lungs, low-dose CT (LDCT) of chest was
applied to lung cancer screening with promising results.9
Therefore, we designed a follow-up strategy using LDCT as
the major surveillance tool for patients with NSCLC who
underwent complete resection. In this study, the frequency
of chest CT was double that used in a previous prospective
study,8 but the same as that for chest radiography used in
most previous retrospective studies.3,5-7 In this 2-part study,
we liked to verify the diagnostic accuracy of LDCT at first and
next to evaluate the clinical significance of LDCT in detect-
ing tumor recurrence of postoperative NSCLC patients.
Patients and Methods
Patients
In part 1, patients who underwent complete resection of NSCLC in
the past 5 years and were subjected to annual postoperative sur-
veillance at our hospital were eligible for this study. The patient
selection criteria were as follows: (1) the patients were regularly
followed up at our hospital; (2) no evidence of tumor recurrence on
last visit; (3) just at the time of the first, second, or fifth annual
surveillance for tumor recurrence when this study was conducted.
In the beginning of this study, the first 30 patients who met the criteria
were enrolled and the surveillance procedures included physical
examination, chest radiography (frontal and lateral projections),
LDCT, and contrast-enhanced standard-dose CT (SDCT) of chest.
In part 2, the patients subjected to completely surgical resection
of NSCLC from January 2000 were invited to participate in this
study. The patient exclusion criteria were as follows: (1) premeno-
pausal woman; (2) patients aged 18 years or younger; (3) patients
with another malignancy in the past 5 years; (4) patients with
reluctance to join the study; or (5) patients having participated in
other follow-up protocols. The preoperative staging work-up was
done as usual at our institute and included chest CT, bronchos-
copy, and whole body bone scan. Abdominal sonography, brain
CT, and mediastinoscopy would be done when clinically indicated
or the disease appeared to be locally advanced. Patients included in
part 2 of the study were informed to visit outpatient clinics every
3 months in the first 2 years and every 6 months for the next 3
years. Physical examination, sputum cytology, serum carcinoem-
bryonic antigen, chest radiography, and LDCT of chest were
performed at each scheduled visit.
The Institutional Review Board of our hospital approved this
study and informed consents were obtained from all patients.
Spiral CT of Chest
The spiral CT scan was performed with Somatom Plus 4 (Siemens,
Forchheim, Germany). After contrast medium injection, SDCT
was obtained from apex to bilateral adrenal glands at 120 kVp, 240
mAs, with 8-mm collimation and table speed of 10 mm/s. We used
the phantom as model and reduced the tube current of spiral CT
from 240 mAs gradually. Finally, we found 43 mAs was the lowest
current that preserved the acceptable image quality. LDCT of chest
was then designed to obtain images at 140 kVp, 43 mAs, with
10-mm collimation and table speed of 20 mm/s. The entire lungs
were scanned without contrast medium. Both CT scans were
performed in a single breath-hold at the end of inspiration and the
films of lung and mediastinum windows were provided to 2 senior
chest radiologists for interpretation. To verify the diagnostic ac-
curacy of LDCT, the images of LDCT in part 1 of the study were
read and discussed by 2 chest radiologists and the consensus
became final. The images of SDCT in part 1 of the study and
LDCT in part 2 of the study were interpreted independently.
The spiral CT findings were classified into three categories.
Pulmonary findings were defined as “negative,” “equivocal,” or
“definite” for newly developed pulmonary lesions. The mediastinal
lymph nodes were defined as “negative,” “positive, insignificant,”
or “positive, significant.” The presence of at least one node larger
than 1 cm in its short axis or the size enlarged as compared with
previous CT was considered significant. The changes of pleura
were recorded as “negative or mild pleural thickening,” “pleural
effusion,” or “suspected metastasis.” The final conclusion of each
CT examination was categorized as “stable,” “suspicious,” or
“suggested recurrence.” Chest radiographs were read in a blind
fashion and categorized as “stable,” “suspicious,” or “suggested
recurrence.”
Recurrence
Patients suspected to have tumor recurrence were admitted and
subjected to brain CT, abdominal sonography, fiberoptic bronchos-
copy, and whole body bone scans. Other diagnostic procedures
were done as indicated. Tissue or fluid specimens were obtained
for cytopathological diagnosis whenever possible. It was catego-
rized “pathological recurrence” if cytopathological examination of
the specimens proved malignancy with same histolopathologic
type as the primary tumor. A diagnosis of “clinical recurrence”
was made when clinical features and results of examinations were
highly suggestive of multiple metastases but tissue diagnosis was
risky or unnecessary.
Statistical Analysis
The agreement of the findings between LDCT and SDCT was
analyzed by Kappa statistics. A P value  .05 was considered
significant. Statistical analysis was carried out with SPSS software,
version 10 (SPSS Inc, Chicago, Ill).
Results
Part 1
In total, 30 cases were included and all underwent chest
radiography, LDCT, and SDCT. The patients at the first,
second, and fifth annual postoperative surveillance were 14,
9, and 7, respectively. The characteristics of the patients are
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summarized in Table 1. SDCT detected 7 recurrent cases, 4
at the first and 3 at the second annual surveillances. LDCT
missed only 1 patient who had diffuse minute metastases in
both lungs with all lesions 1 mm in diameter. The agree-
ment of interpretation between LDCT and SDCT were good
(Table 2). On the contrary, chest radiographs detected only
2 of the 7 with recurrent disease. One was found to have
solitary pulmonary nodule and another had pleural effusion,
nevertheless, chest radiographs failed to detect concurrent
pulmonary metastatic lesions in the later case. Compared
with SDCT, the recurrent case-detection rates of LDCT and
chest radiography were 85.7% and 28.6%, respectively.
Solitary pulmonary nodule was found in 2 of 7 patients
with recurrent disease. One of the 2 patients was a candidate
for second curative operation. After wedge resection of the
tumor and subsequent adjuvant chemotherapy with pacli-
taxel and cisplatin for 6 courses, the patient was included in
part 2 of the study.
Part 2
Between January 2000 and October 2000, 100 patients
underwent surgical resection of proved NSCLC or of soli-
tary pulmonary lesion suspected to be malignant at our
hospital. All were visited preoperatively and invited to
participate in this study if their lung lesions were proved to
be NSCLC and removed completely. The lesions were
benign diseases in 27 cases, NSCLC in 68, metastatic car-
cinoma in 3, and SCLC and atypical carcinoid tumor in 1
each postoperatively. Twenty-five of 68 patients with
NSCLC were excluded based on the following reasons:
unresectable disease in 12 cases, death before the first
follow-up visit in 3, and inability to participate in this study
in 10. The remaining 43 patients were enrolled and followed
up with at least one time of LDCT. The characteristics of the
patients are summarized in Table 3. The median follow-up
time was 15.5 months (3.1-23.5 months). Until January
2002, 5 patients quit and the follow-up rate was 88.4%.
From January 2000 to January 2002, 14 of 38 patients
were found to have recurrent disease. Thirteen of the 14
(92.9%) patients were detected by the surveillance protocol.
The remaining 1 was detected at the unscheduled visit
presenting with generalized bone pain and proved to have
multiple bony metastases by whole body bone scans. Of the
13 patients with recurrent disease detected by surveillance
protocol, 7 were asymptomatic at tumor recurrence. Tumor
recurrence was detected in 11 of 14 patients by LDCT
giving a recurrent case-detection rate of 78.6%. All patients
with evidence or high suspicion of recurrent disease were
admitted to establish a cytopathological diagnosis and re-
search for other metastatic sites (Table 4). One patient who
had solitary pulmonary metastasis was subjected to curative
resection and no tumor recurrence was found in the follow-
ing 8 months.
According to the study design, 180 series of LDCT
should be performed on a fixed schedule. Sixteen series
were carried out using SDCT protocol and another 1 was
missed due to personal reason. Then, a total of 163 series of
LDCT were obtained and analyzed. Among the 19 meta-
static sites found in 14 cases with recurrent disease, LDCT
could detect 11 and provided a recurrent site-detection rate
of 57.9% (11/19). Consequently, every 15 LDCT could
detect 1 recurrent site. In contrast, only 3 patients were
suspected to have recurrent diseases by chest radiography
taken simultaneously.
Discussion
The major rationale of close postoperative follow-up is
based on the findings that the occurrence of second primary
lung cancer is not uncommon and some of the patients with
recurrent disease detected early enough are amenable to
further surgical resection with curative intent.11 The risk of
postoperative NSCLC patients to develop second primary
lung cancer is high and substantial, and estimated about
TABLE 1. General characteristics of patients in part 1 of
this study
No. of patients (%)
Recurrence Stable disease Total
Number 7 (23.3) 23 (76.7) 30
Age (y)
Median/range 66/43-82 69/46-82 69/43-82
Sex
Male/female 4/3 20/3 24/6
Postoperative years
1 4 (28.6) 10 (71.4) 14
2 3 (33.3) 6 (66.6) 9
5 7 (100) 7
Histology
Adenocarcinoma 5 (23.8) 16 (76.2) 21
Squamous cell carcinoma 2 (22.2) 7 (77.8) 9
Pathological staging
T1 N0 M0 2 (28.6) 5 (71.4) 7
T2 N0 M0 4 (26.7) 11 (73.3) 15
T2 N1 M0 1 (50) 1 (50) 2
T3 N0 M0 1 (100) 1
T1 N2 M0 1 (100) 1
T2 N2 M0 4 (100) 4
TABLE 2. Agreement on analyses between low-dose CT
and standard-dose CT
Kappa value 95% CI P value
Pulmonary lesions 0.430 0.165-0.695 .001
Mediastinal lymph node status 0.427 0.174-0.680 .003
Pleural lesions 0.737 0.452-1.016 .001
Overall conclusion 0.902 0.714-1.090 .001
CI, Confidence interval.
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1%-2% per year.12 Accordingly, the patients appear to be
the ones with the highest risk to develop second primary
lung cancer. Furthermore, once recurrent disease occurs,
salvage management is theoretically more effective if tumor
burden is small.13 Consequently, it is plausible that early
detection of tumor recurrence may be of significant merit.
Nevertheless, previous studies revealed no significant dif-
ference in the survival time of NSCLC patients who under-
went either intensive follow-up or less frequent surveillance
postoperatively.3,5-7 The causes remain unknown. There are
two possible explanations. First, most related studies were
retrospective and both the surveillance tests and follow-up
frequency varied widely. Accordingly, the results derived
from these studies are limited. Second, although the expe-
rience of lung cancer screening by chest radiography indi-
cated that early detection did not necessarily translate into
survival benefit,14 a more sensitive screening tool like
LDCT may detect lung cancer in an earlier stage compared
with chest radiography and provide resultant survival ben-
efit. The promising results of LDCT in primary lung cancer
screening did support this rationale.9 In addition, there are
other reasons to support the necessity of regular postoper-
ative follow-up, including the attempts to keep a good
patient-doctor relationship, deal with medicolegal liability,
reduce patient anxiety, and improve surgeons’ technique by
feedback.
Although the definition of local, regional, and distant
recurrence of postoperative lung cancer reported in previous
studies remains inconsistent, most studies indicated that
about one third of first recurrent sites were locoregional and
the rests were distant metastases.2,3,5,15,16 The major sites of
distant metastases were brain, bone, and contralateral lung
and each one accounted for about one third of all distant
metastases. Consequently, it is expected that about half of
the initial recurrent sites might be located in the thorax. To
our knowledge, there was only one published report regard-
ing to prospective follow-up of postoperative NSCLC pa-
tients.8 Their follow-up strategy included physical exami-
nation and chest radiography 1 month after operation and
every 3 months thereafter, and chest CT and fiberoptic
bronchoscopy every 6 months for the first 3 years. For the
next 4 years, chest radiography was performed every 6
months, and chest CT and fiberoptic bronchoscopy once a
year. The results8 showed that the survival time was signif-
icantly longer in patients without symptoms at tumor recur-
rence than in those with. These did support the fact that
intensive follow-up may be of considerable value in early
detection of asymptomatic recurrent disease in patients after
complete resection of NSCLC and improve the survival of
the patients when the recurrent disease is amenable to
curative intent. In addition, the authors8 observed that
asymptomatic recurrent disease was more likely located in
the thorax and readily detected by chest CT and fiberoptic
bronchoscopy. However, the conclusions drawn from this
study8 should be carefully interpreted because of their bi-
ased patient population. About 60% of the patients under-
went pneumonectomy. The skewed characteristics of the
patients might contribute to inordinately high rate of locore-
gional recurrence and overestimate the importance of fiber-
optic bronchoscopy included in the follow-up strategy. De-
spite these flaws, the results seemed encouraging but the
power was not. It was estimated that 2973 patients should be
included in study to provide a 5% survival advantage with
their follow-up strategy.8 We speculate that chest CT can be
a most useful tool in surveillance of recurrent disease in
NSCLC patients after surgical resection if the frequency of
follow-up protocol is adequate.
LDCT of chest has more advantages than does conven-
tional CT in the surveillance of tumor recurrence. First, the
radiation dose is acceptable for repeated examination. The
radiation dose of LDCT can be reduced to about 10%-20%
of SDCT without significant loss of information.17 Accord-
ingly, the radiation dose of 4 LDCT is less than that of 1
TABLE 3. General characteristics of patients in part 2 of
this study
Characteristics
Enrollment
(n  43)
Recurrence
(n  14)*
Age (y)
Median/range 71/51-80 70/62-80
Sex
Male/female 39/4 12/2
Histology
Adenocarcinoma 26 9 (34.6)
Squamous cell carcinoma 10 2 (20)
Adenosquamous cell carcinoma 3 2 (66.7)
Large cell carcinoma 4 1 (25)
Type of operation
Pneumonectomy 1 1 (100)
Bilobectomy 2 1 (50)
Lobectomy 34 12 (27.9)
Segmentectomy/wedge resection 6 0 (0)
Pathological staging†
IA 6 0 (0)
IB 20 6 (30)
IIA 0 0 (0)
IIB 4 1 (25)
IIIA 9 6 (66.7)
IIIB 2‡ 1 (50)
IV 1§ 0 (0)
Recurrent lung cancer 1 0 (0)
*The figures indicate the ratio of recurrent cases over the respective
patient numbers in each subgroup. Values in parentheses are percent-
ages.
†TNM classification and staging was based on the revised international
system for staging lung cancer in 1997.10
‡These 2 patients were found to have satellite lesions in the same lobes
during operation. All these tumors were resected completely.
§This patient had a main tumor in LLL. A metastatic nodule in LUL was
found during operation. Both of the lesions were removed completely.
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SDCT in a year. Second, LDCT can be completed in a
single breath-hold without contrast medium injection. With-
out the risk of anaphylaxis and acute renal failure, LDCT
can be easily and safely performed at outpatient clinics. In
addition, we found that it was not difficult to identify
enlarged mediastinal lymph nodes on noncontrasted LDCT
if preoperative and serial postoperative CT images were
available for comparison.
In this 2-year pilot study, we regularly followed 38
postoperative NSCLC patients with LDCT every 3 months
and found 14 cases with tumor recurrence. The recurrent
pattern was as follows: locoregional in 5 (35.7%), distant in
7 (50%), and both in 2 (14.3%) (Table 4). We searched for
any possible metastatic foci in every patient with newly
diagnosed recurrent disease by brain CT, abdominal sonog-
raphy, fiberoptic bronchoscopy, and whole body bone
scans. Other examinations were performed based on clinical
features. We found a total of 19 first-metastatic sites in 14
patients with recurrent disease, including pleura in 5, lungs
in 4, bones in 4, and mediastinal lymph node, stump, brain,
liver, adrenal gland and skin in 1 each (Table 4). As a
whole, LDCT alone detected 11 of the 14 cases (78.6%)
with recurrent disease and 11 of the 19 first-metastatic sites
(57.9%). Both figures were far beyond our expectation at
the beginning of this study. The reasons were multifactorial.
First, the median follow-up time was 15 months, not long
enough, and the results might just depict the “early” recur-
rent pattern. Second, the recurrent pattern may be somewhat
distorted by the surveillance strategies. We had done our
best to search for other occult metastatic foci, however, we
could still miss the asymptomatic distant metastatic foci due
to limitation of the used screening modalities. Third, the
patient number was limited and the recurrent pattern may be
biased. Of note, pleural metastasis presenting as either ma-
lignant pleural effusion or pleural nodules occurred in 5 of
the 14 patients (35.7%) with recurrent disease. The rate of
tumor recurrence located in pleura was unexpectedly high
and has never been reported before. It is uncertain that
tumor recurrence on pleura is an important but undiscovered
clinical finding or just a biased result. Further studies are
needed to verify this issue.
In our study design, LDCT was substituted for chest
radiography due to the superiority of CT in detecting lesions
in the stump, mediastinal lymph nodes, and pulmonary
parenchyma. Unexpectedly, chest CT proved valuable in
detecting the lesions on chest wall and pleura. Ipsilateral
pleural effusion was not an uncommon finding in NSCLC
patients after complete resection. However, it was absorbed
within 3 to 6 months in most cases. The new-onset or
increasing amount of ipsilateral pleural effusion was highly
suggestive of tumor recurrence on pleura based on this
study. It was readily detected by chest CT but not by chest
radiography attributed to the influence of postoperative
pleural change. In addition, the presence of pleural lesions
provided a safe and easy access for tissue diagnosis of
tumor recurrence. In fact, cytopathologic diagnosis was
made in 8 of 14 patients with recurrent disease in this study
and 5 of the 8 patients was relied on the pleura.
Solitary pulmonary metastasis was found in 3 cases, 2 in
part 1 and 1 in part 2 of this study. The lesion was 1 cm
in diameter in 2 of the 3 cases and both cases were missed
by chest radiography. They were clinically asymptomatic at
tumor recurrence and subjected to curative management.
One underwent wedge resection and another lobectomy.
TABLE 4. Characteristics of individual recurrent patients
No. Sex Age Diagnosis Initial stage Symptom
Detection
method
Disease-free
(mos) Initial metastatic foci
1 M 63 Adenocarcinoma T2 N0 M0 No LDCT 3 Lung
2 M 67 Adenocarcinoma T2 N2 M0 No LDCT 6 Lung
3 M 80 Large cell carcinoma T4 N0 M0 No LDCT 6 Mediastinal lymph nodes
4 M 76 Adenocarcinoma T2 N0 M0 Dyspnea LDCT 6 Pleura, stump, skin
5 M 71 Adenocarcinoma T2 N2 M0 No LDCT 6 Pleura
6 M 69 Adenosquamous cell carcinoma T2 N0 M0 No LDCT 9 Pleura
7 M 66 Squamous cell carcinoma T2 N2 M0 Cough LDCT 9 Pleura
8 M 77 Squamous cell carcinoma T3 N0 M0 Chest pain LDCT 9 Bone
9 M 79 Adenocarcinoma T2 N2 M0 Dyspnea LDCT 12 Pleura, bone, brain
10 F 67 Adenosquamous cell carcinoma T2 N2 M0 No LDCT 12 Lung
11 M 63 Adenocarcinoma T2 N0 M0 No LDCT 15 Lung (solitary nodule)
12* M 67 Adenocarcinoma T2 N0 M0 No US 6 Adrenal, liver
13† M 79 Adenocarcinoma T2 N2 M0 Back pain PET 9 Bone
14 F 79 Adenocarcinoma T2 N0 M0 Bone pain WBBS 5.3 Bone
US, Ultrasonography; PET, positron emission tomography; WBBS, whole-body bone scan.
*Recurrence was initially suspected by elevated serum carcinoembryonic antigen (CEA) level. Abdominal ultrasonography was performed and liver and
adrenal metastases were found. Pathological diagnosis was obtained by liver biopsy.
†Recurrence was suspected due to progressive elevation of serum CEA level and low back pain. Although whole-body bone scan was negative, PET scan
revealed a hot spot over lumbar spine, location of which was compatible with clinical symptom.
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Adjuvant chemotherapy was given in both patients after
operation and no evidence of tumor recurrence was found at
the 22- and 8-month follow-up, respectively.
In summary, our results indicated that thorax was the
most common site of tumor recurrence in NSCLC patients
after complete resection and readily detected by chest CT.
In terms of detecting recurrent disease in such patients,
LDCT of chest was comparable to SDCT but superior to
chest radiography. Postoperative follow-up of NSCLC pa-
tients with LDCT every 3 months in the first 2 years may be
of considerable value in early detection of recurrent disease.
Further studies with larger population and longer studied
period are needed to verify this issue and the cost-benefit.
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